Group 1 - The core viewpoint of the articles indicates that the recent volatility in Hong Kong's technology sector, with the Hang Seng Tech Index dropping 6.5% in a week, is primarily due to liquidity shocks, but the outlook for investing in Hong Kong tech stocks remains positive with high odds and win rates [1] - From the perspective of odds, the discount of Hong Kong tech stocks relative to A-share tech stocks is near historical lows, suggesting significant undervaluation, especially in the context of improved regulatory and economic conditions compared to 2022 and 2023 [1] - In terms of win rates, favorable factors are accumulating, including the peak of overseas liquidity shocks having passed, the effectiveness of the "buy the dip" strategy, and the potential for a rebound as the relative valuation of Hong Kong tech stocks approaches historical lows [1] Group 2 - Investment opportunities in Hong Kong tech-related ETFs are highlighted, including the Hang Seng Tech Index ETF (513180.SH), Hang Seng Internet ETF (513330.SH), and Hong Kong Stock Connect Tech ETF (159101.SZ), which provide low-threshold access for A-share investors [2] - The Hang Seng Internet ETF (513330.SH) focuses on major Hong Kong internet companies such as Alibaba, Baidu, Tencent, and NetEase, while the Hong Kong Stock Connect Tech ETF (159101.SZ) emphasizes leading companies and includes innovative pharmaceutical stocks [2] - These ETFs are listed on mainland stock exchanges and support T+0 intraday trading, offering convenience for investors without the need for cross-border accounts or currency exchange [2]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector, emphasizing the potential for investment in bottom assets within the industry [5]. Core Insights - The report highlights the ongoing opportunities in the pharmaceutical sector, particularly in areas such as AI in medicine and innovative drug developments, while noting the recent market performance where the pharmaceutical sector outperformed the broader market [11][26]. - It emphasizes the importance of monitoring key milestones and data updates from major conferences in 2026, such as AACR and ASCO, which could significantly impact investment decisions [11]. Summary by Sections Market Performance - The pharmaceutical sector has shown a return of 3.28% since the beginning of 2026, outperforming the Shanghai Composite Index by 2.99 percentage points [26]. - Recent weekly performance indicates a slight increase in the pharmaceutical sector by 0.14%, while the broader market declined by 1.33% [11][26]. Investment Opportunities - The report identifies several key areas for investment, including: - IO plus strategies involving VEGF dual antibodies, which are gaining traction in clinical trials [12]. - ADC (Antibody-Drug Conjugates) with a focus on large indications and new indications that could enhance overseas mapping [14]. - The development of new RAS inhibitors and their potential in treating various cancers, highlighting companies like 加科思 and 劲方生物 [15]. - The commercial potential of CDK4/6 inhibitors in HR+ breast cancer, particularly as patents expire [16]. Key Companies and Recommendations - The report recommends several companies for investment, including: - 药明生物, 泰格医药, 先声药业, 康弘药业, 普洛药业, 美好医疗, 迪安诊断, 和铂医药-B, 药石科技, and 天宇股份, all of which are expected to perform well in the current market environment [8][19]. - It notes that the pharmaceutical sector's current valuation is 22.8 times PE based on 2026 earnings forecasts, indicating a premium over the broader A-share market [30]. Clinical Developments - The report discusses various clinical trials and their implications, such as: - The anticipated data readouts for several ADCs and dual antibodies in 2026, which could significantly influence market dynamics [17][20]. - The ongoing advancements in small nucleic acids and their expected commercialization, which could lead to substantial market growth [19][23]. Regulatory Environment - The report highlights the regulatory landscape, noting that the National Medical Insurance Administration will intensify oversight in 2026, which may impact pharmaceutical companies [22]. Overall Sector Outlook - The report maintains a positive outlook on the pharmaceutical sector, suggesting that despite recent market fluctuations, there are significant opportunities for growth and investment, particularly in innovative therapies and technologies [11][19].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [5] Core Insights - The pharmaceutical sector is experiencing a rebound in bottom assets, particularly in traditional Chinese medicine, medical services, and pharmacies, driven by market rotation and price increase expectations in raw materials [7][11] - The report emphasizes the importance of focusing on bottom assets that are expected to see turning points and well-adjusted innovative drug sectors, with a positive outlook on growth directions representing the future of the pharmaceutical industry [11] - Key themes include continuous attention to pharmaceutical and medical AI+, as well as significant data updates expected from major conferences in 2026 [11] Summary by Sections Market Dynamics - The pharmaceutical sector has outperformed the broader market, with a return of 3.28% compared to the Shanghai Composite's 0.29% since the beginning of 2026 [26] - The report notes that the pharmaceutical sector's valuation is currently at 22.8 times PE, with a premium of 11.7% over the overall A-share market [30] Key Company Performance - Recommended stocks for February include WuXi Biologics, Tigermed, and others, with a focus on companies that have shown significant pipeline progress or business development expectations [8][36] - The report highlights the performance of companies like Guangsheng Tang and Nuo Cheng Jian Hua, which have made notable advancements in their core pipelines [36] Industry Trends - The report discusses the trend of combining IO plus therapies and the development of new targets in the dual antibody space, indicating a growing trend in clinical applications [12][14] - Attention is drawn to the ADC (Antibody-Drug Conjugate) sector, particularly large indication FIC (First-in-Class) products and the potential for new indications to enhance overseas mapping [14][17] - The report also highlights the evolving landscape in blood cancers, with new therapies showing promise in previously underserved areas [20]

Core Viewpoint - The recent rebound in the CXO sector is not indicative of a comprehensive recovery but rather a reaction to easily confirmable short-term improvements, particularly among domestic demand-driven CRO and experimental service companies, while leading CDMO companies focused on external demand have underperformed [3][4][5]. Market Dynamics - The market is currently trading based on short-term rebounds rather than a long-term recovery in the CXO industry, with a notable divergence in performance between domestic-focused companies and those reliant on global demand [4][5]. - Despite an overall positive sentiment in the industry, caution remains regarding CDMO companies, which are facing complex pricing environments and geopolitical uncertainties that could impact long-term growth [5][12]. Financial Performance - WuXi AppTec's 2025 performance forecast indicates a revenue of approximately 454.56 billion RMB, a year-on-year increase of about 15.84%, and a net profit of around 191.51 billion RMB, reflecting a significant growth of 102.65% [7]. - The company's revenue growth trajectory has shown consistent improvement throughout the year, with a core business revenue increase of approximately 21.40%, indicating enhanced growth momentum post-divestiture of certain business segments [9][10]. Market Sentiment and Valuation - The market's cautious stance towards CDMO companies is driven by uncertainties regarding future growth, particularly in relation to geopolitical risks and the sustainability of demand for emerging business lines like TIDES [12][13]. - The valuation of CDMO companies reflects a conservative outlook on long-term growth potential rather than immediate revenue uncertainties, leading to a disconnect between fundamental recovery and stock price performance [10][28]. Structural Changes in the Industry - The growth in WuXi AppTec's small molecule D&M business is attributed to an expansion in order structure and capabilities, moving beyond traditional roles to encompass more complex production processes [20][22]. - The acquisition of Dongyao Pharmaceutical by WuXi AppTec highlights a strategic move to secure capacity in a high-demand sector, emphasizing the importance of time as a critical resource in the competitive landscape [24][26]. Conclusion - The current rebound in the CXO sector appears to be driven by emotional and anticipatory factors rather than a full reassessment of long-term industry value, with a clear distinction between domestic and external demand dynamics [28][29].

研究报告 Research Report 9 Feb 2026 香港医疗 Hong Kong Health Care 医药行业周报（2026.02.02-2026.02.06）：市场情绪回暖；看好基本面表现强劲的创新药产业链龙头 Healthcare Weekly (2026.02.02-2026.02.06): Market Sentiment Warms; Bullish on Leaders in Innovative Drug Chain with Strong Fundamentals [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | 评级 | | 百济神州 | Outperform 华润医药 | | Outperform | | 京东健康 | Outperform 国药控股 | | Neutral | | 药明生物 | Outperform 映恩生物 | | Outperform | | 信达生物 | Outperform 金斯瑞生物科 ...

Core Viewpoint - After several days of adjustments, Hong Kong's tech assets have seen a significant rebound, with sectors such as the internet and innovative pharmaceuticals rising together, particularly highlighted by a more than 30% surge in the large model company Zhiyu [1] Group 1: Market Performance - The Hong Kong Stock Connect Technology ETF (159101.SZ) saw its market price increase by nearly 2% during intraday trading, with holdings like Alibaba, Tencent, SMIC, BYD, Hua Hong, BeiGene, and Xpeng all rising over 2% [1] - The PE-TTM of the Hong Kong Stock Connect Technology ETF is at 21 times, which is significantly lower than other major tech indices such as NASDAQ, ChiNext, and STAR Market, positioned at the 30th percentile of the last 10 years [1] Group 2: Sector Coverage - The index of the Hong Kong Stock Connect Technology ETF has filled the gap in innovative pharmaceuticals while also covering leading companies in internet platforms, smart driving, and innovative drugs, including Alibaba, Tencent, BYD, BeiGene, and WuXi Biologics, all of which are eligible for Hong Kong Stock Connect [1] - The ETF is not subject to QDII foreign exchange quota restrictions, providing better liquidity for investors [1] Group 3: Trading Features - The Hong Kong Stock Connect Technology ETF is listed on the Shenzhen Stock Exchange and supports T+0 intraday flexible trading, offering A-share investors a low-threshold option without the need for cross-border accounts or currency exchange [1]

Core Viewpoint - The Hang Seng Technology Index has experienced over 80 trading days of adjustment since October last year, with a drawdown nearing 20%, exceeding historical averages [1] Group 1: Market Performance - The adjustment duration and magnitude have surpassed historical averages, which are 20 trading days and an 18% drawdown respectively [1] - The Hong Kong technology sector is noted for its resilience, while the A-share technology sector is recognized for its greater elasticity [1] Group 2: Investment Outlook - Huaxia Fund is optimistic about the rebound potential of Hong Kong technology stocks, highlighting the sector's core assets in AI, including computing power, models, software applications, and hardware terminals [1] - The integration of AI with e-commerce, entertainment, and enterprise services is expected to generate significant products [1] Group 3: Investment Products - Investors are encouraged to consider Hong Kong technology-related ETFs, such as the Hang Seng Technology Index ETF (513180.SH), Hang Seng Internet ETF (513330.SH), and Hong Kong Stock Connect Technology ETF (159101.SZ), all of which are listed on mainland exchanges and support T+0 trading [1] - The Hang Seng Internet ETF (513330.SH) focuses on major Hong Kong internet companies like Alibaba, Baidu, Tencent, NetEase, and JD.com [1] - The Hong Kong Stock Connect Technology ETF (159101.SZ) covers internet and new energy vehicles while also including leading innovative pharmaceutical companies like BeiGene, WuXi Biologics, and Innovent Biologics [1]

Core Viewpoint - The Hang Seng Technology Index has experienced a decline due to tax concerns and the impact of the AI "red envelope war" on profitability, falling below the 250-day moving average, which has historically served as a support line during major market rallies [1] Group 1: Market Performance - The Hang Seng Technology Index has dropped below the 250-day moving average, a critical support level that has not been significantly breached during previous major market rallies, including those in 2016-2017 and 2020-2021 [1] - After several days of trading below the 250-day moving average, the Hang Seng Technology Index has begun to rebound, indicating that the short-term downward momentum has been sufficiently released [1] Group 2: Fund Flows - Recent large net subscriptions have been observed in technology-related ETFs such as the Hang Seng Technology Index ETF (513180.SH), Hang Seng Internet ETF (513330.SH), and the Hong Kong Stock Connect Technology ETF (159101.SZ), suggesting that funds may be optimistic about the current valuation [1] - The Hang Seng Internet ETF (513330.SH) focuses on major Hong Kong internet giants including Alibaba, Baidu Group, Tencent Holdings, and NetEase, while the Hong Kong Stock Connect Technology ETF (159101.SZ) includes leading innovative pharmaceutical companies like BeiGene, WuXi Biologics, and Innovent Biologics [1]

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors considering the value of more R&D pipelines when evaluating valuations [1] Group 1: Investment Strategy - Companies are now trading based more on actual execution capabilities rather than solely on licensing deal expectations [1] - Achieving returns that exceed the industry average this year will rely more on key data releases, actual transactions, and visibility on profit realization or turning points [1] Group 2: Sector Analysis - The outlook for CDMO companies is becoming more constructive due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - The ratings for WuXi AppTec and WuXi AppTec Holdings have been upgraded to "Buy" [1] Group 3: Selective Strategy in Biotech and Pharma - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing some promise, along with actual transaction expectations [1] - Companies such as Kelun-Biotech, Innovent Biologics, and Hansoh Pharmaceutical are viewed positively [1] Group 4: Medical Devices Sector - The medical devices sector maintains a neutral outlook, as the industry has bottomed out but requires time for gradual recovery [1] - Recommendations include buying Angelalign Technology and Weigao Group [1]

Investment Rating - The report maintains a "Buy" rating for the medical services industry, suggesting a positive outlook for investment opportunities in this sector [10][64]. Core Insights - The medical services sector has shown resilience, with a recent increase in the sector's PE ratio to 34.43X and PB ratio to 3.49X, indicating a positive trend in valuation metrics [4][29]. - The approval of internet medical first diagnosis trials in Beijing marks a significant regulatory breakthrough, potentially accelerating the online medical service process and providing new market opportunities for private medical institutions [5][62][63]. - The report highlights the importance of digital regulation and standardization in enhancing service capabilities for private medical institutions, particularly in consumer healthcare sectors like pediatrics and dermatology [5][62]. Summary by Sections Industry Performance - The pharmaceutical and biological sector increased by 0.14%, ranking 15th among 31 primary industries, outperforming the Shanghai Composite Index by 1.47 percentage points [2][12]. - The medical services sub-sector reported a 1.31% increase, closing at 6827.17 points, with a year-to-date performance of 41.41% [24][27]. Company Performance - Top-performing companies in the medical services sector include Meidisi (+18.0%), Tongce Medical (+8.1%), and Nuosige (+5.7%), while underperformers include Haoyuan Pharmaceutical (-6.2%) and Baicheng Pharmaceutical (-4.5%) [3][27]. Valuation Metrics - The medical services sector's PE ratio has increased by 0.56X from the previous week, while the PB ratio has risen by 0.06X, indicating a strengthening in market confidence [4][29]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO in the pharmaceutical outsourcing sector, as well as companies like WuXi AppTec and Haoyuan Pharmaceutical [10][64]. - It also recommends monitoring private medical service providers with compliance experience, such as Aier Eye Hospital, as they are expected to benefit from the evolving regulatory landscape [5][64].